Breaking Finance News

Puma Biotech. (NYSE:PBYI) price target upped to $111.00, issued a ratings update earlier today by Credit Suisse

Just yesterday Puma Biotech. (NYSE:PBYI) traded 2.99% higher at $67.97. Puma Biotech.’s 50-day moving average is $55.30 and its 200-day moving average is $39.51. The last stock price is up 77.18% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 910,848 shares of PBYI traded hands, up from an average trading volume of 805,627

Stating as potential upside of 0.63%, Credit Suisse upped the target price of Puma Biotech. (NYSE:PBYI) to $111.00

Previously on Wednesday September 21, 2016, Stifel Nicolaus released a statement about Puma Biotech. (NYSE:PBYI) increased the target price from $61.00 to $88.00. At the time, this indicated a possible upside of 0.35%.

Recent Performance Chart

Puma Biotech. (NYSE:PBYI)

Puma Biotech. has 52 week low of $19.74 and a 52 week high of $94.93 and has a market capitalization of $0.

In addition to Credit Suisse reporting its stock price target, a total of 6 brokerages have issued a research note on the company. The average stock price target is $95.50 with 2 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 2 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Puma Biotech. (NYSE:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.